Trial Profile
Safety of ocriplasmin intravitreal injection in patients with focal vitreomacular adhesion with exudative age-related macular degeneration.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jun 2015
Price :
$35
*
At a glance
- Drugs Ocriplasmin (Primary)
- Indications Age-related macular degeneration; Retinal disorders
- Focus Therapeutic Use
- 25 Jun 2015 New trial record
- 01 Apr 2015 Results published in the Ophthalmology.